OncoMatch/Clinical Trials/NCT07458347
A Phase 1 Dose Escalation and Dose Expansion Trial of KST-6051 in Participants With Advanced Solid Tumors With Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Mutation
Official title: A First-in-human Phase 1 Dose Escalation and Dose Expansion Study Evaluating the Safety, Pharmacokinetics, Pharmacodynamics, and Preliminary Efficacy of KST-6051 in Patients With Advanced or Metastatic Solid Tumors With a KRAS Mutation
Is NCT07458347 recruiting? Yes, currently enrolling (Oct 2026). This Phase 1 trial studies multiple treatments for kras-mutant non-small cell lung cancer (nsclc).
Treatment: KST-6051 · Gemcitabine/nab-paclitaxel · Cetuximab · Pembrolizumab · mFOLFOX6 · FOLFIRI · Pemetrexed · Carboplatin — The main purpose of the trial is to assess whether the trial drug, KST-6051, is safe and tolerable when administered orally, alone or in combination with other anticancer agents, to adults with advanced or metastatic solid tumors with certain KRAS mutations.
Check if I qualifyExtracted eligibility criteria
Treatments studied
Immunotherapy
Targeted therapy
Chemotherapy
Other
Cancer type
Non-Small Cell Lung Carcinoma
Pancreatic Cancer
Colorectal Cancer
Tumor Agnostic
Biomarker criteria
Required: KRAS mutation
Performance status
ECOG 0–1(Restricted strenuous activity)
Lab requirements
Blood counts
adequate hematological function
Kidney function
adequate renal function
Liver function
adequate liver function
Cardiac function
adequate cardiovascular function
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- Cedars-Sinai Medical Center · Los Angeles, California
- Florida Cancer Specialists · Sarasota, Florida
- Moffitt Cancer Center · Tampa, Florida
- Mass General Brigham Cancer Institute at Massachusetts General Hospital · Boston, Massachusetts
- Sidney Kimmel Cancer Center · Philadelphia, Pennsylvania
Showing up to 5 US sites.
See all sites on ClinicalTrials.gov →Frequently asked questions
Is NCT07458347 currently recruiting?
Yes, this trial is currently recruiting patients.
Does this trial require KRAS?
Yes, KRAS mutation is a required biomarker for enrollment.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify